Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Investigating Potential Mechanism(s) By Which ASO-Based Drugs Cause Thrombocytopenia

Martina H. Lundberg Slingsby, PhD, Genevieve Couldwell, Prakrith Vijey, Brooke E Terkovich, Leila Noetzli, PhD, Ross Okazaki, Jonathan N. Thon, PhD, Scott P. Henry, PhD, Padmakumar Narayanan, DVM, PhD, Joseph E. Italiano, Jr., PhD

Blood (2018) 132 (Supplement 1): 3747.

https://doi.org/10.1182/blood-2018-99-116590

Published: 2018

Journal Articles

Relative Abundance Analysis of the Oral and Gastrointestinal Microbiome during Autologous Transplantation for Multiple Myeloma: Results of a Prospective Pilot Study and Association with Transplant Outcomes

Najla H El Jurdi, MD, Ali Filali, PhD, Iman Salem, MD, Mauricio Retuerto, MS, Nina Dambrosio, CNP, Hillard M Lazarus, MD, Richard Creger, PharmD, Paolo F Caimi, MD, Brenda Cooper, MD, Ben Tomlinson, MD, Leland Metheny, MD, Ehsan Malek, MD, Folashade Otegbeye, MBBChir, MPH, Rafick-Pierre Sekaly, PhD, Mahmoud Ghannoum, PhD, Marcos de Lima, MD

Blood (2018) 132 (Supplement 1): 5754.

https://doi.org/10.1182/blood-2018-99-120125

Published: 2018

Journal Articles

Diversity and Richness Analysis of the Oral and Gastrointestinal Microbiome during Autologous Transplantation for Multiple Myeloma: Results of a Prospective Pilot Study and Correlation with Transplant Outcomes

Najla H El Jurdi, MD, Ali Filali, PhD, Iman Salem, MD, Mauricio Retuerto, MS, Nina Dambrosio, CNP, Hillard M Lazarus, MD, Paolo F Caimi, MD, Richard Creger, PharmD, Brenda Cooper, MD, Ben Tomlinson, MD, Leland Metheny, MD, Ehsan Malek, MD, Folashade Otegbeye, MBBChir, MPH, Rafick-Pierre Sekaly, PhD, Mahmoud Ghannoum, PhD, Marcos de Lima, MD

Blood (2018) 132 (Supplement 1): 4627.

https://doi.org/10.1182/blood-2018-99-120038

Published: 2018

Journal Articles

Targeting the Mechanism of c-Mpl Exon-Inclusion through Antisense Oligonucleotides Yields a Dominant Negative Isoform

Sakiko Suzuki, MD, Ronny R Racine, PhD BS, Nathan A Manalo, MS, Neeraj Saini, MD, Cliff Odour, Michael Moazami, MS, Jeffrey A Bailey, MD PhD, Jonathan K Watts, PhD, Glen D. Raffel, MD PhD

Blood (2017) 130 (Supplement 1): 383.

https://doi.org/10.1182/blood.V130.Suppl_1.383.383

Published: 2017

Journal Articles

Pharmacokinetics and Biodistribution of Locked Nucleic Acid (LNA)-Mir-221 Inhibitor: A New Promising Anti-Myeloma Agent

Maria Eugenia Gallo Cantafio, PhD, Annamaria Gulla, MD, Nicola Amodio, PhD, Emanuela Leone, PhD, Eugenio Morelli, MD, Lavinia Biamonte, PhD, Antonino Neri, Pr, MD, Pierosandro Tagliaferri, MD, Pierfrancesco Tassone, MD, Maria Teresa Di Martino

Blood (2015) 126 (23): 3025.

https://doi.org/10.1182/blood.V126.23.3025.3025

Published: 2015

Journal Articles

Randomized Trial of a Novel CMV Vaccine (CMVPepVax) after Allogeneic HCT: Elevated CMV-Specific Immune Response, Reduction in Chronic GvHD and CMV Reactivation Only in Vaccine Arm Patients

Ryotaro Nakamura, MD, Corinna La Rosa, PhD, Jeff Longmate, PhD, Margaret O'Donnell, MD FRCPC, Ji-Lian Cai, MD, Len Farol, MD, Amandeep Salhotra, MD, David S Snyder, MD, Jennifer Drake, Cynthia Slape, James Merson, PhD, John A Zaia, MD, Stephen J. Forman, Don J. Diamond, PhD

Blood (2014) 124 (21): 183.

https://doi.org/10.1182/blood.V124.21.183.183

Published: 2014

Journal Articles

In Vitro and Vivo Activity Against Multiple Myeloma Cells Of a Novel Locked Nucleic Acid (LNA)-Mir-221 Inhibitor

Maria Teresa Di Martino, PhD, Annamaria Gullà, MD, Maria Eugenia Gallo Cantafio, Emanuela Altomare, PhD, Nicola Amodio, PhD, Emanuela Leone, PhD, Santo Giovanni Lio, Eugenio Morelli, MD, Daniele Caracciolo, MD, Cirino Botta, MD, Antonino Neri, MD, Niels M Frandsen, PhD, Pierosandro Tagliaferri, MD, Pierfrancesco Tassone, MD

Blood (2013) 122 (21): 3166.

https://doi.org/10.1182/blood.V122.21.3166.3166

Published: 2013

Journal Articles

Targeted Repression of TP53 Promotes Erythropoiesis in Del(5q) MDS and Overcomes Clinical Resistance to Lenalidomide

Gisela Caceres, Joe Johnson, Kathy L. McGraw, Ashley A. Basiorka, Kenian Liu, Ph.D., Larry J Smith, Ph.D., F. Joseph Daugherty, MD, Sheng Wei, MD, Rami S. Komrokji, MD, Ling Zhang, MD, Neil Littleton, MD, Richard A. Wells, MD, DPhil, Lubomir Sokol, MD, Ph.D, Alan F List, MD

Blood (2012) 120 (21): 920.

https://doi.org/10.1182/blood.V120.21.920.920

Published: 2012

Journal Articles

Oblimersen (OBL; Genasense®), a Phosphorothioate (PS) Bcl-2 Antisense Oliogonucleotide (ASO), Can Be Safely Administered by Bolus Subcutaneous (SC) Injection and Brief IV Infusion.

Anthony Tolcher, Thomas Julian, Anila Qureshi

Blood (2007) 110 (11): 4724.

https://doi.org/10.1182/blood.V110.11.4724.4724

Published: 2007

Journal Articles

In Vivo CpG Administration Accelerates Graft-Versus-Host Disease (GVHD) Lethality by Toll-Like Receptor 9 (TLR9) Ligation of Host Antigen-Presenting Cells (APCs) and Promotes Allogeneic Bone Marrow (BM) Rejection by TLR9 Ligation of Donor APCs.

Bruce R. Blazar, Angela Panoskaltsis-Mortari, Arthur M. Krieg, Hiroaki Hemmi, Shizuo Akira, Jonathan Serody, William J. Murphy, Patricia A. Taylor

Blood (2006) 108 (11): 446.

https://doi.org/10.1182/blood.V108.11.446.446

Published: 2006

Journal Articles

dSLIM Immunomodulators Induce Anti-Tumor Responses Both In Vitro and In Vivo .

Manuel Schmidt, Javier de Cristobal, Astrid Sander, Bernadette Brzezicha, Sven A. König Merediz, Burghardt Wittig

Blood (2006) 108 (11): 1727.

https://doi.org/10.1182/blood.V108.11.1727.1727

Published: 2006

Journal Articles

dSLIM Immunomodulators Induce Anti-Tumor Responses Both In Vitro and In Vivo .

Manuel Schmidt, Javier de Cristobal, Astrid Sander, Bernadette Brzezicha, Sven A. Koenig-Merediz, Burghardt Wittig

Blood (2005) 106 (11): 5527.

https://doi.org/10.1182/blood.V106.11.5527.5527

Published: 2005

Journal Articles

Potent Phosphorodiester-Based DNA Immunomodulators (dSLIM) Exhibit Enhanced Safety Compared to Phosphorothioate-Based Oligonucleotides.

Manuel Schmidt, Javier de Christobal, Nicole Hagner, Astrid Sander, Alberto Marco, Sven A. Koenig-Merediz, Burghardt Wittig

Blood (2005) 106 (11): 3915.

https://doi.org/10.1182/blood.V106.11.3915.3915

Published: 2005

Journal Articles

A Novel 2′-Deoxy-2′-Fluoro (2′F-ANA) Ribose Modification Significantly Enhances the Duration, and Efficiency, of Nucleic Acid Mediated Gene Silencing.

Anna Kalota, MS, Lidia Karabon, PhD, Cezary S. Swider, PhD, Ekaterina Viazovkina, PhD, Mohamed Elzagheid, PhD, Masad J. Damha, PhD, Alan M. Gewirtz, MD

Blood (2005) 106 (11): 3062.

https://doi.org/10.1182/blood.V106.11.3062.3062

Published: 2005

Journal Articles

Inhibition of Bcl-2 by Anti-Sense Oligonucleotide and siRNA in Specimens from Patients with Waldenström’s Macroglobulinemia (WM).

Gwen L. Nichols, M.D., Luba Benimetskaya, Ph.D., Cy A. Stein, M.D.Ph.D.

Blood (2004) 104 (11): 2294.

https://doi.org/10.1182/blood.V104.11.2294.2294

Published: 2004

Journal Articles

Rapid Ex Vivo Expansion of CMV Specific CTL Suitable for Clinical Immunotherapy Using CpG-DNA Matured PBMC Infected with Recombinant MVA.

Don J. Diamond, PhD, Zhongde Wang, PhD, Simon F. Lacey, PhD, Corinna La Rosa, PhD

Blood (2004) 104 (11): 5102.

https://doi.org/10.1182/blood.V104.11.5102.5102

Published: 2004

Journal Articles

Effect of hTERT Antisense on Cisplatin Sensitivity of Acute Lymphoblastic Leukemic Cells.

Wenyu Li, MD, Yuan Zhang, PhD

Blood (2004) 104 (11): 4358.

https://doi.org/10.1182/blood.V104.11.4358.4358

Published: 2004

Journal Articles

CpG Combined with Chemotherapy in the Immunotherapy of Large Tumor.

Jiali Li, Ph.D., Ronald Levy, MD

Blood (2004) 104 (11): 3275.

https://doi.org/10.1182/blood.V104.11.3275.3275

Published: 2004

Journal Articles

Intracellular Levels of Oblimersen Sodium and Target Downregulation Correlates to Clinical Activity of bcl-2 Antisense in Acute Myeoid Leukemia (AML).

Guido Marcucci, W. Stock, G. Dai, S. Liu, R. Klisovic, M. I. Klisovic, D. Sher, L. Huynh, S. Frankel, W. Blum, R. A. Larson, M. R. Grever, J. C. Byrd, K. K. Chan

Blood (2004) 104 (11): 1170.

https://doi.org/10.1182/blood.V104.11.1170.1170

Published: 2004

Journal Articles

Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia

Blood (2003) 101 (2): 425–432.

https://doi.org/10.1182/blood-2002-06-1899

Published: 2003

NARROW

Investigating Potential Mechanism(s) By Which ASO-Based Drugs Cause Thrombocytopenia

Relative Abundance Analysis of the Oral and Gastrointestinal Microbiome during Autologous Transplantation for Multiple Myeloma: Results of a Prospective Pilot Study and Association with Transplant Outcomes

Diversity and Richness Analysis of the Oral and Gastrointestinal Microbiome during Autologous Transplantation for Multiple Myeloma: Results of a Prospective Pilot Study and Correlation with Transplant Outcomes

Targeting the Mechanism of c-Mpl Exon-Inclusion through Antisense Oligonucleotides Yields a Dominant Negative Isoform

Pharmacokinetics and Biodistribution of Locked Nucleic Acid (LNA)-Mir-221 Inhibitor: A New Promising Anti-Myeloma Agent

Randomized Trial of a Novel CMV Vaccine (CMVPepVax) after Allogeneic HCT: Elevated CMV-Specific Immune Response, Reduction in Chronic GvHD and CMV Reactivation Only in Vaccine Arm Patients

In Vitro and Vivo Activity Against Multiple Myeloma Cells Of a Novel Locked Nucleic Acid (LNA)-Mir-221 Inhibitor

Targeted Repression of TP53 Promotes Erythropoiesis in Del(5q) MDS and Overcomes Clinical Resistance to Lenalidomide

Oblimersen (OBL; Genasense®), a Phosphorothioate (PS) Bcl-2 Antisense Oliogonucleotide (ASO), Can Be Safely Administered by Bolus Subcutaneous (SC) Injection and Brief IV Infusion.

In Vivo CpG Administration Accelerates Graft-Versus-Host Disease (GVHD) Lethality by Toll-Like Receptor 9 (TLR9) Ligation of Host Antigen-Presenting Cells (APCs) and Promotes Allogeneic Bone Marrow (BM) Rejection by TLR9 Ligation of Donor APCs.

dSLIM Immunomodulators Induce Anti-Tumor Responses Both In Vitro and In Vivo .

dSLIM Immunomodulators Induce Anti-Tumor Responses Both In Vitro and In Vivo .

Potent Phosphorodiester-Based DNA Immunomodulators (dSLIM) Exhibit Enhanced Safety Compared to Phosphorothioate-Based Oligonucleotides.

A Novel 2′-Deoxy-2′-Fluoro (2′F-ANA) Ribose Modification Significantly Enhances the Duration, and Efficiency, of Nucleic Acid Mediated Gene Silencing.

Inhibition of Bcl-2 by Anti-Sense Oligonucleotide and siRNA in Specimens from Patients with Waldenström’s Macroglobulinemia (WM).

Rapid Ex Vivo Expansion of CMV Specific CTL Suitable for Clinical Immunotherapy Using CpG-DNA Matured PBMC Infected with Recombinant MVA.

Effect of hTERT Antisense on Cisplatin Sensitivity of Acute Lymphoblastic Leukemic Cells.

CpG Combined with Chemotherapy in the Immunotherapy of Large Tumor.

Intracellular Levels of Oblimersen Sodium and Target Downregulation Correlates to Clinical Activity of bcl-2 Antisense in Acute Myeoid Leukemia (AML).

Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only